The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

T elemedicine company GoodRx ( GDRX) has been helping Americans find the cheapest way to buy drugs for years. Thanks to a new ...

Novo Nordisk stock rose after good news from the FDA on Wegovy—it’s popular weight-loss drug which has the same active ...

Eli Lilly & Novo Nordisk target cash-pay customers in the GLP-1 weight loss market with $499 monthly offers. Read more here.

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Pharmaceutical powerhouse Novo Nordisk (NYSE:NVO) is charging 3.1% higher to trade at $54.10, after its weight-loss drug ...

GoodRx is collaborating with Novo Nordisk to offer its weight-loss drugs to self-paying patients at lower costs. The prescription-drug provider said Monday that all strengths of Ozempic and Wegovy ...

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a [form of liver disease]( ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...